ONC Stock Price, Performance & Company Data

ONC shares rise after BeOne Medicines reports Q2 revenue up 30% YoY and raises 2026 revenue guidance to $6.6–$6.8 billion.

4 hours ago·Lightyear AI

13:30

15:10

16:45

18:25

20:00

About BeOne Medicines AG

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.

Ticker

$ONC

Sector

Health

Primary listing

NASDAQ

Employees

12,000

Headquarters

Basel, Switzerland

Website

beonemedicines.com

ONC Metrics

BasicAdvanced

$37bn

59.01

$5.59

0.50

Bulls say / Bears say

At ASCO 2026, BeOne presented 78-month follow-up data showing durable progression-free survival with Brukinsa in frontline CLL, reinforcing its clinical differentiation in that setting (markets.ft.markitdigital.com)

FT reported landmark Phase 3 data at EHA 2026 demonstrating sustained disease control with Brukinsa in patients aged 80+ with CLL, underscoring its efficacy in high-risk elderly populations (markets.ft.markitdigital.com)

BeOne reported net income of $286.9 million and generated $941.7 million in free cash flow for full-year 2025, marking its first sustainable profitability and bolstering its R&D funding capacity (tradingview.com)

Brukinsa’s outsized contribution to revenue—net product sales of $3.93 billion out of $5.28 billion in 2025—implies a ~74% concentration risk if Brukinsa faces competitive or safety setbacks (sec.gov)

BeOne’s full-year 2026 revenue guidance midpoint of $6.3 billion fell $141 million short of the $6.441 billion analyst consensus, triggering a >2% share decline following Q4 results (investing.com)

A pending AbbVie trade-secrets lawsuit alleging misappropriation of technology by a former scientist poses potential financial liabilities and reputational damage (news.bloomberglaw.com)

Data summarised monthly by Lightyear AI. Last updated on 7 Aug 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

BeOne’s full-year 2026 revenue guidance midpoint of $6.3 billion fell $141 million short of the $6.441 billion analyst consensus, triggering a >2% share decline following Q4 results (investing.com)

A pending AbbVie trade-secrets lawsuit alleging misappropriation of technology by a former scientist poses potential financial liabilities and reputational damage (news.bloomberglaw.com)

Data summarised monthly by Lightyear AI. Last updated on 7 Aug 2026.